A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

NCT05662397 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Relapsed Cancer
Refractory Cancer

Interventions

DRUG: HST-1011
BIOLOGICAL: Cemiplimab

Sponsor

HotSpot Therapeutics, Inc